Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for severe respiratory diseases, with its lead candidate, AV-101, specifically targeting the underlying causes of lung inflammation and fibrosis. The company addresses critical unmet medical needs in respiratory health through a robust pipeline and a commitment to next-generation treatment solutions. With an experienced leadership team and a distinguished scientific advisory board, Avalyn is strategically positioned to enhance patient outcomes and capture an expanding market in respiratory therapeutics.

AVLN · Avalyn Pharma